"Factor Xa Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Endogenous factors and drugs that inhibit or block the activity of FACTOR XA.
| Descriptor ID |
D065427
|
| MeSH Number(s) |
D27.505.519.389.745.800.449.500 D27.505.954.502.119.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Factor Xa Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Factor Xa Inhibitors".
This graph shows the total number of publications written about "Factor Xa Inhibitors" by people in this website by year, and whether "Factor Xa Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 |
| 1996 | 0 | 1 | 1 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 0 | 1 |
| 2003 | 0 | 2 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 1 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 4 | 2 | 6 |
| 2016 | 5 | 2 | 7 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 2 | 4 |
| 2019 | 6 | 0 | 6 |
| 2020 | 3 | 2 | 5 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
| 2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Factor Xa Inhibitors" by people in Profiles.
-
Use of Direct Oral Anticoagulants in Patients With Peripheral Artery Disease: A Meta-Analysis. Am J Cardiol. 2024 Sep 01; 226:34-35.
-
The Use of Apixaban for Postoperative Venous Thromboembolism Prophylaxis in Gynecologic Cancer. Ann Surg Oncol. 2024 Aug; 31(8):4855-4857.
-
Predictors of adherence to direct oral anticoagulants after cardiovascular or bleeding events in Medicare Advantage Plan enrollees with atrial fibrillation. J Manag Care Spec Pharm. 2024 May; 30(5):408-419.
-
A meta-analysis of direct oral anticoagulants vs warfarin for left ventricular thrombus. Prog Cardiovasc Dis. 2024 Jul-Aug; 85:114-117.
-
Efficacy, safety, and feasibility of Apixaban for postoperative venous thromboembolism prophylaxis following open gynecologic cancer surgery at a comprehensive cancer center. Gynecol Oncol. 2024 04; 183:120-125.
-
Real-world use of apixaban for the treatment and prevention of thrombosis in children with cardiac disease. J Thromb Haemost. 2023 06; 21(6):1601-1609.
-
Direct oral to parenteral anticoagulant transitions: Role of factor Xa inhibitor-specific anti-Xa concentrations. Pharmacotherapy. 2022 10; 42(10):768-779.
-
Managing bleeding risk after cold snare polypectomy in patients receiving direct-acting oral anticoagulants. Gastrointest Endosc. 2022 05; 95(5):969-974.
-
Reassessing the Pediatric Dosing Recommendations for Unfractionated Heparin Using Real-World Data: A Pharmacokinetic-Pharmacodynamic Modeling Approach. J Clin Pharmacol. 2022 06; 62(6):733-746.
-
Indirect antiplatelet effects of rivaroxaban in a patient with intracranial hemorrhage: An underappreciated coagulopathy of factor Xa inhibitors? Am J Emerg Med. 2022 01; 51:426.e5-426.e7.